Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Amgen 4Q Results

Ten products deliver double-digit sales growth in the quarter, including Repatha, up 45% to $606 million.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Amgen

Amgen

4Q Revenues: $9.1 billion (+11%)

4Q Earnings: $627 million (-18%)

FY Revenues: $33.4 billion (+19%)

FY Earnings: $4.1 billion (-39%)

Comments: Product sales grew 11%, primarily driven by 14% volume growth. Excluding sales from the Horizon Therapeutics acquisition, product sales grew 10%.

Ten products delivered double-digit sales growth in the quarter, including Repatha, up 45% to $606 million, BLINCYTO, up 58% to $381 million, TEZSPIRE, up 67% to $296 million, EVENITY, up 36% to $431 million, and TAVNEOS, up 84% to $81 million.

Prolia sales were up 5% to $1.2 billion in the quarter. Enbrel sales were flat at $1.0 billion.

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS.

Earnings reflect acquisition-related costs related to the Horizon acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics